Gilead Sciences (NASDAQ:GILD)

health care

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Many investors want to try to find the stocks that are going to offer the traditional “beat and raise estimates” before they release quarterly earnings reports. Actually, it has always ...
Read Full Story »
Money background. Close-up.

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences Inc. (NASDAQ: GILD) reported its third-quarter results after the market close on Monday as $1.84 in earnings per share and $6.04 billion in revenue. That was against Thomson ...
Read Full Story »
biotech

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its third-quarter earnings after the U.S. markets close on Tuesday. Thomson Reuters has consensus estimates of $1.92 in earnings per shares ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific

The short interest data are out for the October 15, settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Biotechnology word cloud

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

The recent market sell-off spared no sector, and the top biotechnology stocks were treated with their own trip to the woodshed. Rising trends in prescriptions and higher, yet beatable increases ...
Read Full Story »
Cisco logo

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

After a 14-year secular bear market that finally ended when the S&P 500 broke solidly above the 1,600 level in the summer of last year, prompting a move to record ...
Read Full Story »
Disney logo

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Typically midterm election years are good years for the stock market. While there is no guarantee that this year will follow the past, there is a good chance that the ...
Read Full Story »
research

Short Sellers Make Moves in Key Biotech Stocks

The short interest report is out for the September 15 settlement date, and here 247 Wall St. has decided to focus on the biotech sector. Short sellers are often active ...
Read Full Story »
health care

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

For a variety of reasons, the cases of chronic hepatitis in the United States have surged dramatically over the past 20 years. Currently, it is estimated that more than 3.2 ...
Read Full Story »
Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »
Biotechnology word cloud

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

Biotech stock investing can be a nerve-racking experience for investors, especially if they are focused on the companies that are waiting on some sort of binary event or clinical data ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More

Stocks were firm yet again on Friday morning ahead of the PPI wholesale inflation report. Investors have been trying to decide where to put their money after the recent stock ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More

Stocks were firm on Monday morning, looking to add to the recovery bounce from Friday. Investors have now been given an opportunity to look for stocks that have pulled back ...
Read Full Story »
Comcast-Logo

Oppenheimer Adds 5 Triple-Play Rated Stocks to Buy

The tougher the going gets in the stock market, the more investors want to make very sure they have their bets on companies that have every possible attribute working in ...
Read Full Story »
biotech

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

A brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The ...
Read Full Story »